BOULDER, Colo., June 13 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM - News) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing and established a six month review goal for the Company’s new drug application (NDA) supplement to add IV administration to instructions in the prescribing information for its demethylating agent Vidaza® (azacitidine for injectable suspension). This targets an agency response on or before September 29, 2006.
